Atox Bio closes $30M round as it speeds through late-stage trials
Israel’s Atox Bio has raised $30 million — the latest in a long line of equity deals — to help push its immune modulators through late …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
